ADHD Meds May Help Control Opioid Use Disorder in Pregnancy
By Lori Solomon HealthDay Reporter
TUESDAY, June 25, 2024 -- Psychostimulants may help opioid use disorder (OUD) outcomes in pregnant women, according to a study published online June 11 in Nature Mental Health.
Kevin Y. Xu, M.D., M.P.H., from the Washington University School of Medicine in St. Louis, and colleagues used U.S. multistate administrative data to examine the risks and benefits of attention-deficit/hyperactivity disorder (ADHD) medication among 3,247 pregnant women initiating OUD treatment, with 5 percent receiving psychostimulants.
The researchers found that compared to peers not receiving psychostimulants, individuals receiving psychostimulants had greater buprenorphine (adjusted relative risk, 1.81) but lower methadone initiation (adjusted relative risk, 0.39). Among psychostimulant recipients who initiated buprenorphine, lower buprenorphine discontinuation was seen among those receiving psychostimulants versus nonrecipients (adjusted hazard ratio, 0.77). Person-days (defined by psychostimulant fills) were associated with fewer substance use disorder-related admissions versus days without fills in within-person case-crossover analyses (odds ratio, 0.50).
"These findings highlight important potential benefits of pharmacologically treating ADHD with stimulants in pregnant people with concomitant OUD and ADHD," the authors write. "Future studies are warranted to clarify pregnancy and neonatal outcomes when treating this specific population to further inform share decision-making."
One author disclosed ties to the pharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Prescribing ADHD Meds by Telehealth Does Not Alter Risk for Substance Use Disorder Overall
TUESDAY, June 17, 2025 -- Receipt of a stimulant prescription for attention-deficit/hyperactivity disorder (ADHD) via telehealth is not associated with an increased risk for...
Youth Deaths Attributable to Synthetic Opioids Alone Increasingly Predominant
THURSDAY, May 29, 2025 -- Among U.S. youth, overdose deaths attributable to synthetic opioids alone are increasingly predominant, according to a study published online May 20 in...
Exercise May Provide Protection for Childhood Psychiatric Conditions
THURSDAY, May 15, 2025 -- Physical activity (PA) and participation in organized sports may offer protective effects against childhood psychiatric conditions, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.